

## Daclizumab

Cat. No.:	HY-108738
CAS No.:	152923-56-3
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	-80°C

# Daclizumab

### BIOLOGICAL ACTIVITY

<b>Description</b>	Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 ( $\alpha$ -subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25 and prevents the interaction of IL-2 with the IL-2R-HA. Daclizumab (Zenapax) can be used for multiple sclerosis research <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IL-2

### REFERENCES

[1]. Stanley L Cohan, et al. Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis. Biomedicines. 2019 Mar 11;7(1):18.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA